Showing results (101-110 of 222) with videos related to

Sort By:
Pageof 23
Cancer Chemotherapy and Pharmacology|December 9, 2010
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsElisabeth I Heath, George R Blumenschein, Roger B Cohen, et al.
Preventive Medicine Reports|July 14, 2023
The impact of high intensity interval training in a diverse group of cancer survivors: CAPABLE, a pilot studyJennifer L Beebe-Dimmer, David G Finlay, Julie J Ruterbusch, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2011
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancerVincent Chung, Elisabeth I Heath, William R Schelman, et al.
Advances in Radiation Oncology|July 21, 2021
A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate CancerMuhammad Hamid, Lance K Heilbrun, Jordan Maier, et al.
Investigational New Drugs|September 3, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancerElisabeth I Heath, Wei Chen, Lance Heilbrun, et al.
International Journal of Molecular Sciences|July 2, 2021
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer CellsMd Hafiz Uddin, Yiwei Li, Husain Yar Khan, et al.
Surgical Endoscopy|June 20, 2000
The role of laparoscopy in preoperative staging of esophageal cancerE I Heath, H S Kaufman, M A Talamini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate CancerAnthony V Serritella, Daniel Shevrin, Elisabeth I Heath, et al.
Investigational New Drugs|November 20, 2015
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) studyManish K Thakur, Lance K Heilbrun, Shijie Sheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183Linda E Bröker, Stephan A Veltkamp, Elisabeth I Heath, et al.
Pageof 23